Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients

Nephrology Dialysis Transplantation

Volumn 18, Issue SUPPL. 3, 2003, Pages

  Date, Toshiyuki ^a   Shigematsu, Takashi ^a   Kawashita, Yoshiteru ^a   Satake, Nobuyoshi ^a   Morita, Kyoko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colestimide; End stage renal disease; Hyperphosphataemia; Phosphate binder

Indexed keywords

ALFACALCIDOL; ALUMINUM; CALCIUM; CALCIUM CARBONATE; CHOLESTEROL; COLESTILAN; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MALE; METEORISM; PHOSPHATE BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; UREMIA;

ADULT; ANION EXCHANGE RESINS; CALCIUM; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPICHLOROHYDRIN; FEMALE; HUMANS; IMIDAZOLES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHATES; RESINS, SYNTHETIC; UREMIA;

EID: 18144436894     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Block GA, Port FK. Re-evaluation of risks associated with uremia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237
2. Van de Vyver FL, De Broe ME. Aluminum in tissues, Clin Nephrol 1985; 24 [Suppl 1]: S37-S57
3. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997; 29: 641-649
4. Chertow GM, Burke SK, Dillon MA, Slatopolsky E for the RenaGel Study Group. Long-term effect of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-2914
5. Fung F, Sherrard DJ, Gillen DL et al. Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis 2002; 40: 307-314
6. Almaden Y, Hernandez A, Torregrosa V et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998; 9: 1845-1852
7. Saito Y and MCI-196 Study Group. The long-term study of MCI-196 on hypercholesterolemia. J Clin Ther Med 1996; 12: 1305-1347
8. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
9. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
10. Chertow GM, Dillon MA, Burke SK et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Clin Nephrol 1999; 51: 18-26
11. Edwards RM. Disorders of phosphate metabolism in chronic renal disease. Curr Opin Pharmacol 2002; 2: 171-176